Table 2A. EFS and OS for all patients by MYCN oncogene status, MYCN-P status, and MYC-P status.
| Cohort | Number | 4-year EFS ± SE (%) |
EFS p-value | 4-year OS ± SE (%) |
OS p-value |
|---|---|---|---|---|---|
| Overall | 241 | 56.2 ± 5.5 | N/A | 64.5 ± 5.4 | N/A |
|
MYCN Non-amplified Amplified |
121 (50%) 120 (50%) |
58.8 ± 10.9 53.2 ± 6.3 |
0.1701 | 70.7 ± 9.9 59.3 ± 6.3 |
0.0913 |
| MYCN-P (−)/(+/−) (+) |
128 (53%) 113 (47%) |
61.4 ± 9.9 50.4 ± 6.5 |
0.0337 | 73.8 ± 8.9 55.9 ± 6.5 |
0.0096 |
| MYCN-P by MYCN Non-amplified, (−)/(+/−) Non-amplified, (+) Amplified, (−)/(+/−) Amplified, (+) |
111 (46%) 10 (4%) 17 (7%) 103 (43%) |
59.1 ± 11.4 52.5 ± 36.2 76.9 ± 18.5 50.0 ± 6.6 |
0.1601 | 72.4 ± 10.2 39.4 ± 30.7 84.6 ± 16.6 56.3 ± 6.6 |
0.0656 |
| MYC-P (−)/(+/−) (+) |
199 (83%) 42 (17%) |
57.0 ± 5.8 51.0 ± 17.8 |
0.9244 | 65.0 ± 5.7 58.0 ± 16.8 |
0.7212 |
| MYC-P by MYCN Non-amplified, (−)/(+/−) Non-amplified, (+) Amplified, (−)/(+/−) Amplified, (+) |
82 (34%) 39 (16%) 117 (49%) 3 (1%) |
62.5 ± 12.8 50.2 ± 20.5 53.2 ± 6.4 50.0 ± 35.4 |
0.4793 | 76.2 ± 11.2 55.5 ± 18.5 58.8 ± 6.4 100.0 ± 0.0 |
0.2312 |
| MYCN-P, MYC-P Both (−)/(+/−) Either or Both (+) |
91 (38%) 150 (62%) |
66.3 ± 11.1 50.2 ± 6.2 |
0.0131 | 80.1 ± 9.5 56.1 ± 6.1 |
0.0064 |